What is Azacitidine Drug?
Azacitadine is a cytotoxic chemotherapy drug. This medication is classified as an antimetobolite and a demethylating agent. This medication is used to treat a group of blood/bone marrow disorders (myelodysplastic syndromes-MDS) in which the bone marrow does not produce enough healthy blood cells. People with MDS usually have problems such as infections, anemia, and easy bleeding/bruising. Azacitidine is a chemotherapy drug.
The market study is broken down by Type (Acute myeloid leukemia (AML) and Myelodysplastic syndrome (MDS)), by Application (Refractory anemia (RA), Refractory anemia with excess blasts (RAEB), Chronic myelomonocytic leukemia (CMMoL) and Others) and major geographies with country level break-up.
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that Players from United States will contribute to the maximum growth of Global Azacitidine Drug market throughout the predicted period.
Celgene (United States), Mylan N.V. (United States), Shilpa Medicare (United States), Pfizer Inc. (United States), Teva Pharmaceuticals (Israel), Sandoz (Germany), Sanofi (France), GlaxoSmithKline (United Kingdom), Novartis (Switzerland) and Dr. Reddy's Laboratories (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Sun Pharmaceutical Industries Ltd. (India), Natco Pharma (India) and Accord Healthcare (India).
AdvanceMarketAnalytics has segmented the market of Global Azacitidine Drug market by Type, Application and Region.
On the basis of geography, the market of Azacitidine Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Route of Administration, the sub-segment i.e. Oral will boost the Azacitidine Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Online will boost the Azacitidine Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Dose, the sub-segment i.e. 100 mg will boost the Azacitidine Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospital will boost the Azacitidine Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
On 1st September 2020, the Food and Drug Administration approved azacitidine tablets (ONUREG, Celgene Corporation) for continued treatment of patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.
- Rising Research and Development Activities to Develop Azacitidine Drug
- Increasing Number of the Population with the Myelodysplastic Syndromes (MDS) Disorder
- Growing Pharmaceuticals Industry across the Globe
- Increasing Demand From Developing Nations
- Various Side Effects Like Low Blood Counts
- Strict Norms and Regulations
Key Target AudienceAzacitidine Drug panel Manufacturers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others
About ApproachDuring this study the evaluation and validation of the market size is done through various sources including primary and secondary analysis. AMA Research & Media follows industrial and regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand companys positioning regarding market value, volume and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase